Real-world treatment patterns among patients diagnosed with metastatic castration-sensitive prostate cancer (mCSPC) in community oncology settings.

5074 Background: Androgen deprivation therapy (ADT) served as standard of care for mCSPC for decades. Combining ADT with docetaxel (DOC) starting in 2015 or with novel hormonal therapies (NHT) starting in 2017 has demonstrated improved survival compared to ADT alone. This study examined the impact of new evidence on treatment selection for mCSPC patients in real-world oncology practice. Methods: Electronic medical record (EMR) data from a...